PAROXYSMAL NOCTURNAL HEMOGLOBINURIA THERAPEUTICS MARKET ANALYSIS

Paroxysmal Nocturnal Hemoglobinuria Therapeutics Market, by Drug Type (Eculizumab and Ravulizumab), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022-2028

To Be Published : Dec 2024
Code : CMI2542
Formats :
Excel and PDF
Industry : Pharmaceutical

Regional Analysis

Global Paroxysmal Nocturnal Hemoglobinuria Therapeutics Market: Regional Analysis

North America is expected to dominate in paroxysmal nocturnal hemoglobinuria therapeutics market during the forecast period, owing to new approvals from the FDA. For instance, in 2018, Ravulizumab (Ultomiris) from Alexion Pharmaceuticals and APL2 from Apellis Pharmaceuticals was approved by the FDA, for the treatment of paroxysmal nocturnal hemoglobinuria.

Asia Pacific paroxysmal nocturnal hemoglobinuria therapeutics market size is expected to witness significant growth due to availability of cost-effective treatment and medical tourism for PNH. According to an article published by National Center for Biotechnology Information (NCBI) in 2014, the cost of bone marrow transplant in India was between US$ 10,000 and US$ 40,000 in 2014 and in the U.S., it was between US$ 73,000 and US$ 140,000 in 2012.

By Region